116 results about "Desoxycholic acid" patented technology

The invention discloses a preparation method of a doxorubicin-loaded ginseng selenium polysaccharide nano-carrier with immunoregulation and liver cancer cell inhibition functions, and aims to solve the problems of toxic injury of tissues and organs and inhibition of an immune system caused by an antitumor drug doxorubicin. According to the invention, deoxycholic acid is grafted on the ginseng selenium polysaccharide, so that the ginseng selenium polysaccharide is hydrophobized and forms an amphiphilic polysaccharide polymer, and the limitations of large molecular weight, low bioavailability and the like of the ginseng selenium polysaccharide are overcome. The self-assembled ginseng selenium polysaccharide nanoparticles are used as carriers for delivering antitumor drugs, so that the self-assembled ginseng selenium polysaccharide nanoparticles have an immunoregulation effect and can effectively improve side effects such as immunosuppression caused by the antitumor drugs; and the carrier also has a pH sensitive response release characteristic, so that the targeting effect of the medicine in a tumor area is enhanced, and the innovative carrier has a good clinical application prospect.

The invention discloses a ferredoxin mutant and application of the ferredoxin mutant in synthesis of murine deoxycholic acid, and belongs to the technical field of biological catalytic enzymes. According to the invention, Escherichia coli is used as a chassis strain to express P450 enzyme OleP, a three-component redox partner library is established, and a redox partner PetH / PetF which is most adaptive to OleP is screened. A high-throughput method based on a characteristic light absorption value is developed, and the lithocholic acid and the murine deoxycholic acid can be rapidly and efficiently detected. And the ferredoxin mutant PetFF64D is screened through semi-rational design of the ferredoxin, so that the conversion rate of catalytically preparing the murine deoxycholic acid can be greatly improved. The method provides a new strategy for improving the biosynthesis of hydroxylated steroids.

The invention relates to a construction method and application of a bile acid fingerprint spectrum in bile, and relates to the technical field of traditional Chinese medicine detection. The construction method comprises the following steps: preparing a reference substance solution: weighing at least two of taurocholic acid, taurodeoxycholic acid, glycocholic acid, cholic acid and glycodeoxycholic acid reference substances, and preparing the reference substance solution; preparing a test sample solution, namely filtering bile, taking filtrate, heating in a gradient manner, drying and grinding to obtain a test sample, and preparing the test sample solution; and constructing a fingerprint spectrum: respectively injecting the reference substance solution and the test solution into a high performance liquid chromatograph, and determining under a predetermined liquid phase condition to construct the bile acid fingerprint spectrum. The construction method can be used for fully and effectively separating and identifying various bile acid components in the bile, can be used for simultaneously detecting and measuring the various bile acid components in the bile, and has important significance in the aspects of quality control, authenticity identification, basic research on pharmacodynamic substances and the like of the bile.

An Alzheimer's disease biomarker based on a brain metabolite and a use thereof. The biomarker comprises any one or a combination of at least two of palmitic acid, DHA, gallic acid, 11Z,14Z,17Z-eicosatrienoic acid, glycodeoxycholic acid, palmitoleic acid, linoleic acid, erucic acid, petroselinic acid, and arachidonic acid. The level of a metabolite is detected to assist in early diagnosis of the Alzheimer's disease, thus facilitating rapid detection; in addition, the present invention has the characteristics of timeliness, convenience, high specificity and high sensitivity.

The invention discloses a feed additive for preventing broiler necrotic enteritis, a preparation method and application, and relates to the technical field of feed. Comprising the following raw materials in parts by weight: 15-30 parts of plant essential oil, 40-60 parts of deoxycholic acid, 10-20 parts of vitamin D310, 3-8 parts of protein zinc, 2-6 parts of saccharomyces cerevisiae and 1-5 parts of zeolite powder. The feed additive provided by the invention is clear in component, stable in property, convenient to operate and control, easy to realize industrial production, and convenient to popularize and apply. By adopting the feed additive provided by the invention, the integrity of the intestinal epithelial barrier can be improved, the intestinal flora structure can be improved, the immunity of the organism can be improved, and necrotic enteritis of broilers can be effectively prevented.

The invention belongs to the technical field of biomedicine, and particularly provides a periodontitis related marker which comprises glycochenodeoxycholic acid. The concentration change of the periodontitis related marker provided by the invention is directly related to the pathological mechanism of periodontitis. As bound bile acid, the bile acid is slowly degraded in saliva. And the glycochenodeoxycholic acid in the saliva is synthesized from gingival fibroblasts, so that the influence of systemic inflammatory diseases is greatly eliminated. Glycine chenodeoxycholic acid in saliva is used as a specific biomarker, a non-invasive, high-sensitivity and high-specificity detection method, system and equipment are established, objective quantitative evaluation and dynamic monitoring of periodontitis activity are achieved, the hysteresis limitation of traditional diagnosis is broken through, a convenient and non-invasive accurate diagnosis tool is provided for clinic, and the clinical application prospect is wide. And the technical blank of periodontitis activity noninvasive diagnosis is filled.

To provide cellular uptake.SOLUTION: The invention provides a bile acid or a pharmaceutically acceptable salt thereof for use in a method for treating the human or animal body, the method comprises administering to the human or animal body a therapeutic compound, where: a. the bile acid is chenodeoxycholic acid or deoxycholic acid; b. optionally, the bile acid is employed in conjunction with EDTA; c. in the method, the bile acid or salt thereof and EDTA are used to enable or enhance intracellular uptake of the therapeutic compound.SELECTED DRAWING: None

The invention discloses a synthesis method of N-goose deoxycholyl-L-aspartic acid and application of the N-goose deoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolism-related fatty liver diseases. According to the method provided by the invention, chenodeoxycholic acid and L-dimethyl aspartate hydrochloride are taken as raw materials, and a chenodeoxycholic acid-dimethyl aspartate intermediate is synthesized, so that a target compound-N-chenodeoxycholyl-L-aspartic acid with a brand new structure is efficiently prepared. The compound shows a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as fatty degeneration, inflammation and fibrosis of the liver. The invention provides a brand new solution for major clinical challenges of insufficient curative effect, large side effect, drug withdrawal rebound and the like of the current MAFLD treatment drug, and provides a candidate compound with a wide prospect for developing a novel efficient MAFLD treatment drug.

An embodiment of the present invention relates to: a cancer antigen peptide nanostructure comprising an assembly of cancer antigen peptides conjugated with deoxycholic acid; a method for preparing same; and use thereof. The inventors of the present invention confirmed that the nanostructure of the present invention effectively stimulates the maturation of dendritic cells, migrates to lymph nodes, and activates T cells. Also, in a cancer cell model, significant infiltration of cytotoxic T lymphocytes into primary tumors was observed, and an anti-metastatic effect was confirmed. Therefore, the nanostructure according to the present invention can be effectively used as a promising immunotherapy platform that can be applied to various intractable cancers.

The invention discloses application of secondary bile acid in preparation of an anti-tumor drug and the anti-tumor drug. The secondary bile acid comprises taurocholic acid, glycocholic acid, glycodeoxycholic acid and taurodeoxycholic acid, and the taurocholic acid and the glycocholic acid can inhibit the growth of tumor cells, reduce the migration ability of the tumor cells and promote the apoptosis of the tumor cells; glyminodeoxycholic acid and taurodeoxycholic acid can effectively promote infiltration of M1 macrophages in a tumor tissue immune microenvironment, so that tumor cells are identified and cleared by mediation of the M1 macrophages, and tumors are inhibited; besides, the glycodeoxycholic acid / taurodeoxycholic acid combined immune checkpoint inhibitor can significantly inhibit the growth of liver cancer tumors, has the effects of promoting anti-tumor immunity and further cooperatively inhibiting tumor growth, can be applied to tumor treatment, and has considerable clinical significance and economic value.

The invention relates to a metabolite marker for early diagnosis of colorectal cancer as well as application and a device of the metabolite marker. The marker comprises sulfate, ubiquinone-1, a deoxycholic acid glycine conjugate, demethylchlorophyllin, 3-(3, 5-diiodine-4-hydroxyphenyl) lactate, vitamin K1, O-decanoyl-L-carnitine, sedoheptulose 1, 7-diphosphoric acid, cholesterol-docosahexaenoic acid ester and acyl AMP (adenosine monophosphate). The marker combination has excellent performance in colorectal cancer detection, AUROC can reach 0.97, and noninvasive screening and early diagnosis of colorectal cancer can be accurately, quickly and simply realized.

The application provides a reduction-responsive nano delivery system and application thereof in preparation of a drug for treating drug-resistant tumors, and belongs to the pharmaceutical field. The application constructs a reduction-responsive branched copolymer functionalized by pegylation and deoxycholic acid (DA) (referred to as: pegylated branched poly(HPMA-DA)), which can effectively encapsulate small molecule drugs to form a nano delivery system. Experiments prove that the nano delivery system can be taken up by tumor cells, has good tumor targeting, and exhibits excellent anti-tumor effect in tumor xenografts (CDX) derived from non-small cell lung cancer (NSCLC) chemoresistant cell lines and patient-derived xenograft mouse models (PDX). The pegylated branched poly(HPMA-DA) provided by the application has wide application prospect in preparation of a drug carrier, and the nano delivery system provided by the application has wide application prospect in preparation of a drug for treating cancer.

The present invention relates to the field of animal breeding technology, and in particular to the use of porcine deoxycholic acid in reducing animal fat deposition. The present invention uses UCP1 genetically modified pigs with a low-fat phenotype to conduct targeted metabolic analysis in feces, and discovers and identifies a pig intestinal endogenous metabolite that can reduce fat deposition, porcine deoxycholic acid, whose chemical formula is C 24 H 40 O4. The present invention finds that the content of swine deoxycholic acid can indicate the fat deposition ability of pigs, and oral administration of swine deoxycholic acid to mice can significantly reduce the fat deposition of mice. The swine deoxycholic acid provided by the present invention has the effect of reducing fat deposition, and can be developed as a feed additive for reducing pig fat deposition in the future. At the same time, it can be applied to the research and development of drugs for reducing human obesity, providing a scientific basis for the treatment of human obesity and other diseases.

The invention belongs to the field of biology, discloses a variant of 7 alpha-hydroxysteroid dehydrogenase, and aims to improve the catalytic efficiency and stability of catalyzing chenodeoxycholic acid (CDCA) to be converted into UDCA precursor 7-ketolithocholic acid, and particularly, the variant is obtained by carrying out single mutation or multipoint combined mutation on the 93th site, the 94th site, the 96th site, the 146th site, the 150th site, the 155th site, the 188th site, the 189th site, the 190th site, the 195 site, the 195th site, the 196th site, the 196th site, the 195th site, the 195th site, the 195th site, the 196th site, the 199th site, the 200th site, the 204th site and the 249th site

The invention belongs to the technical field of biological medicine, and relates to a novel application of endogenous substances in alcohol related liver disease (ALD). The invention proposes for the first time that an endogenous substance with regular concentration change in the ALD process can be used as a biomarker for auxiliary diagnosis and / or stage evaluation of ALD, the exogenous supplement of the endogenous substance has a prevention and treatment effect on ALD, and the endogenous substance has double values of being used as an excellent biomarker and an effective therapeutic agent. The substances include but are not limited to taurochenodeoxycholic acid (TCDCA), dehydroepiandrosterone sulfate (DHEA-S) and the like. Wherein the serum concentration of TCDCA is obviously increased along with disease progression, and the concentration of DHEA-S is obviously reduced. The diagnostic value of the substance on ALD is remarkably superior to that of a traditional liver injury marker, and ethanol-induced liver cell injury and mouse liver pathological change can be remarkably improved through exogenous supplementation. The invention provides a brand new strategy for accurate diagnosis and prevention of ALD.

The invention belongs to the technical field of biological medicines, and particularly relates to application of chenodeoxycholic acid in preparation of drugs for treating allergic diseases. It is found that CDCA can effectively inhibit pyroptosis and secretion of proinflammatory factors, expression of complement inhibition proteins CD46, CD55 and CD59 is remarkably up-regulated, expression of the complement inhibition proteins CD46, CD55 and CD59 is finally promoted, and occurrence and development of allergic diseases are effectively relieved. In a mouse model, CDCA can significantly improve OVA-induced food allergy symptoms, and has application prospects in treatment of allergic diseases.

The invention provides a traditional Chinese medicine composition for improving eyesight and removing nebula and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition comprises bear gall powder and borneol in a mass ratio of (1-5): 1. The bear gall powder is prepared from taurodeoxycholic acid and taurodeoxycholic acid arginine salt according to the molar ratio of (0.4 to 0.9) to (0.1 to 0.6). According to the application, taurodeoxycholic acid in the bear gall powder is converted into taurodeoxycholic acid arginine salt, so that the molar ratio of taurodeoxycholic acid to taurodeoxycholic acid arginine salt in the bear gall powder is (0.4-0.9): (0.1-0.6), and the bear gall powder is used for treating cataract after being compounded with borneol. Experimental results show that when the molar ratio of taurodeoxycholic acid to taurodeoxycholic acid arginine salt in the bear gall powder is (0.4-0.9): (0.1-0.6), the effect of treating cataract by compounding the bear gall powder with borneol is obviously superior to that of only taurodeoxycholic acid in the bear gall powder or only taurodeoxycholic acid arginine salt in the bear gall powder; for example, significant differences exist in the aspects of relieving the opacity degree and thickness of the crystalline lens.

The invention discloses a blood lipid quality control liquid, which comprises a buffer solution, cholesterol or cholesterol and glycerol, cholic acid or deoxycholic acid and salt thereof, and cyclodextrin. According to the blood fat quality control liquid, cholic acid or deoxycholic acid and salt thereof and cyclodextrin are used as solubilizers to form a compound, cholesterol is dissolved in a water-soluble matrix, direct normal-temperature stirring is performed, no organic flammable harmful reagent participates, the process is simple, safe and reliable, the stability is good, and the effective period can reach 12 months.

The invention provides two new applications of taurochenodeoxycholic acid (TCDCA) in the field of alcohol related liver diseases (ALD), and belongs to the field of biological medicines. First, the invention proposes that TCDCA is used as a biomarker for auxiliary diagnosis and / or staging evaluation of ALD for the first time. Clinical research finds that the level of TCDCA in human serum is in significant positive correlation with the severity of ALD, and the TCDCA has extremely high accuracy in ALD diagnosis and can effectively assist in distinguishing different stages of diseases. Secondly, the invention discloses an application of TCDCA in preparation of a medicine for preventing and / or treating ALD (Atomic Lymphosis Disease). Researches show that the TCDCA can save ethanol-induced liver cell activity decline in a concentration-dependent manner and improve liver pathological indexes of mice. The TCDCA has double values of being used as an excellent biomarker and an effective prevention and treatment component, and a brand new strategy is provided for accurate diagnosis and prevention and treatment of ALD.

The application discloses a synthesis method of N-chenodeoxycholyl-L-aspartic acid and application of the N-chenodeoxycholyl-L-aspartic acid in preparation of a medicine for improving metabolic associated fatty liver disease. The method provided by the application uses chenodeoxycholic acid and L-aspartic acid dimethyl ester hydrochloride as raw materials, synthesizes a chenodeoxycholic acid-aspartic acid dimethyl ester intermediate, and efficiently prepares a target compound, N-chenodeoxycholyl-L-aspartic acid, which is a novel structure, the compound exhibits a treatment effect superior to that of obeticholic acid (OCA) in an animal model, and can effectively improve multiple indexes such as liver steatosis, inflammation and fibrosis. The application provides a novel solution for major clinical challenges such as insufficient treatment effect, large side effect and rebound after drug withdrawal of current MAFLD treatment medicines, and provides a candidate compound with broad prospects for developing a new high-efficiency MAFLD treatment medicine.

The present invention relates to a lipolytic injection composition having excellent effects of alleviating pain during treatment, and improving solubility and maintaining stability of deoxycholic acid by comprising deoxycholic acid (DCA) and cyclodextrin in an optimal composition ratio and adjusting pH to a range of 7.0 to 7.7.

The invention discloses an application of glycine ursodeoxycholic acid in prevention and treatment of periodontitis. Experiments such as RT-qPCR (Reverse Transcription-Quantitative Polymerase Chain Reaction) and the like on a cellular level prove that the GUDCA can inhibit inflammatory reaction of bone marrow-derived macrophages; meanwhile, TRAP dyeing, RT-qPCR and other experiments prove that the GUDCA can inhibit osteoclastic differentiation of the BMDM. The traditional Chinese medicine composition can inhibit macrophage inflammatory response and osteoclast differentiation, and inhibit mouse periodontitis inflammatory response and bone resorption in vivo, so that occurrence and development of periodontitis are prevented and treated, and the traditional Chinese medicine composition can become a novel medicine for clinically preventing and treating periodontitis.

The present invention provides a fat-dissolving composition and a use thereof. The fat-dissolving composition of the present invention comprises a pharmaceutically active ingredient, an inclusion material, a pH regulator optionally selected from one or more of a buffer, a stabilizer, an osmotic pressure regulator, and a complexing agent, and optionally purified water, wherein the pharmaceutically active ingredient is selected from one or more of deoxycholic acid, a pharmaceutically acceptable salt of deoxycholic acid, and a deoxycholic acid derivative, and the amount of the inclusion material ranges from 4% to 35% on the basis of the total weight of the fat-dissolving composition. Compared with conventional formulations at the same dose, the fat-dissolving composition of the present invention can significantly reduce adverse effects at the administration site while having a good fat-dissolving effect, and has higher safety.

The invention provides a fat-dissolving composition and application thereof. The fat-dissolving composition comprises an active pharmaceutical ingredient, an inclusion material, a pH regulator, one or more optional components selected from a buffering agent, a stabilizing agent, an osmotic pressure regulator and a complexing agent, and optional purified water, the active pharmaceutical ingredient is selected from one or more of deoxycholic acid, pharmaceutically acceptable salts of deoxycholic acid and deoxycholic acid derivatives, and the dosage range of the inclusion material is 4-35% based on the total weight of the fat-dissolving composition. Compared with a conventional preparation with the same dosage, the fat-dissolving composition disclosed by the invention has the advantages that under the condition that a good fat-dissolving effect is achieved, the adverse reaction of an administration part can be obviously relieved, and the fat-dissolving composition has higher safety.

This invention belongs to the field of traditional Chinese medicine technology, and provides the application of Scutellaria baicalensis leaf aqueous extract in the preparation of drugs for improving or treating inflammatory bowel disease (IBD) with depression. The Scutellaria baicalensis leaf aqueous extract improves IBD with depression by increasing the abundance of Akkermansia myxophilus (AKK) bacteria, restoring disordered deoxycholic acid metabolism. The extract increases the abundance of AKK bacteria in the intestine, increases the content of deoxycholic acid (DCA) in the intestine, regulates Th17 / Treg homeostasis, reduces intestinal inflammation, maintains intestinal barrier integrity, reduces the entry of pro-inflammatory factors into the bloodstream and across the blood-brain barrier into the hippocampus, inhibits neuroinflammation, and improves depression. Scutellaria baicalensis leaves can improve IBD with depression by increasing the abundance of AKK bacteria in the intestine, increasing intestinal DCA levels, regulating Th17 / Treg balance, repairing the intestinal barrier, reducing LPS leakage and alleviating nerve damage, and inhibiting the inflammatory response of the gut-brain axis. This provides certain experimental evidence for the development and utilization of related traditional Chinese medicine resources.

The invention discloses human body simulation fasting gastric juice and a preparation method thereof, and belongs to the technical field of in-vitro dissolution experiments of pharmaceutical preparations. The invention aims to solve the problems that in the prior art, simulated gastric juice has significant differences with real empty gastric juice of a human body in the aspects of surface tension, osmotic pressure and buffer capacity, so that an in-vitro evaluation result of a dissolution behavior of a pharmaceutical preparation is inaccurate, and scientificity and reliability of an in-vitro dissolution experiment of a drug are influenced. The human body simulated fasting gastric juice comprises the following components: 2 to 30 mg / mL of bovine serum albumin, 0 to 7.517 E-05 mol / L of glycocholic acid or glycocholate, 0 to 7.421 E-05 mol / L of glycochenodeoxycholic acid or glycochenodeoxycholate, 0 to 8.369 E-04 mol / L of taurocholic acid or taurocholate, 0 to 9.005 E-04 mol / L of taurochenodeoxycholic acid or taurochenodeoxycholate, 0.025 to 0.138 g / L of calcium chloride, 0.478 to 1.12 g / L of potassium chloride, 0.015 to 0.063 g / L of magnesium chloride, 2.05 to 5.26 g / L of sodium chloride, 0.037 to 0.411 g / L of sodium dihydrogen phosphate and a pH regulator. The method can be used for evaluating the dissolution behavior of the pharmaceutical preparation in vitro, and is suitable for the fields of drug development, quality control and the like.

This application discloses a lipid control solution, comprising a buffer solution, cholesterol or cholesterol and glycerol, cholic acid or deoxycholic acid and its salts, and cyclodextrin. The lipid control solution provided in this application uses cholic acid or deoxycholic acid and its salts and cyclodextrin as solubilizers to form a complex, allowing cholesterol to dissolve in a water-soluble matrix. It is prepared by direct stirring at room temperature, without the involvement of any organic flammable or harmful reagents. The process is simple, safe, reliable, and exhibits good stability with a shelf life of up to 12 months.

The invention provides application of ergosterol in preparation of a medicine for treating pulmonary arterial hypertension. The preparation method of the ergosterol comprises the following steps: cleaning, crushing and drying silkworm chrysalis cordyceps hainanensis sporocarp to obtain cordyceps militaris powder; the method comprises the following steps: mixing cholic acid, deoxycholic acid, methoxypolyethylene glycol and absolute ethyl alcohol to obtain ethanol mother liquor of a supramolecular solvent; carrying out gradient synergistic extraction on the cordyceps militaris extract; carrying out reduced pressure distillation and drying to obtain an extract, and carrying out chromatographic separation and drying; and recrystallizing, cleaning and drying to obtain the product. According to the invention, CO2 expanded ethanol liquid is adopted as a solvent, a cholic acid-deoxycholic acid-methoxypolyethylene glycol supramolecular solvent system technology and homologous adaptability of steroid nucleus structures of etocholic acid and deoxycholic acid and ergosterol are utilized to construct a multi-stage cavity recognition network, and C5-C6 double bonds and C22-C23 double bonds of ergosterol are specifically combined, so that the detection sensitivity of ergosterol is improved, and the detection sensitivity of ergosterol is improved. Meanwhile, the pore diameter of the cavity is regulated and controlled through methoxypolyethylene glycol, and the content of ergosterol in the extract is increased.

The application discloses a deoxycholic acid intermediate and application thereof, and belongs to the technical field of organic synthesis. The deoxycholic acid intermediate has a structural formula as shown in the specification, wherein R1 is -OH or -OAc; R2 is alpha-OH, beta-OH or =O; and R3 is =O or -CHCH3. In addition, the application further provides application of the deoxycholic acid intermediate in preparation of deoxycholic acid. The intermediate can be used for effectively and safely synthesizing deoxycholic acid.

The invention discloses a nano-micelle for targeted delivery of deoxycholic acid and IPI-549 and application of the nano-micelle. Deoxycholic acid, EDC.HCl and NHS are taken and dissolved in DMSO, deionized water in which hyaluronic acid is dissolved is dropwise added, and hyaluronic acid-deoxycholic acid micelle HA-D is synthesized. The hyaluronic acid-deoxycholic acid and the IPI-549 are subjected to self-assembly, and the hyaluronic acid-deoxycholic acid / IPI-549 nano-micelle HA-D / I is finally prepared. Hyaluronic acid is selectively combined with CD44 molecules highly expressed in a brain glioma area, and drug molecules and nano-particles can be delivered to the brain glioma area. Therefore, hyaluronic acid is used as a skeleton of HA-D / I, the nano-micelle containing deoxycholic acid and IPI-549 is delivered to a brain glioma area, and accurate administration treatment is realized.